Johnson & JohnsonNYSE
Mon, Dec. 5, 5:04 PM
Mon, Dec. 5, 7:45 AM
- AstraZeneca (NYSE:AZN) has finalized its agreement with Johnson & Johnson's (NYSE:JNJ) Cilag GmbH International for the divestment of the ex-U.S. rights to Rhinocort Aqua, a nasal spray for allergic and non-allergic rhinitis and nasal polyps.
- Under the terms of the deal, AstraZeneca received a payment of $330M. The payment will be recorded as "Other Operating Income" this quarter.
Mon, Dec. 5, 2:53 AM
- Novartis (NYSE:NVS) CEO Joe Jimenez has played down suggestions the drugmaker could bid for Swiss biotech group Actelion (OTCPK:ALIOY), which is in talks with Johnson & Johnson (NYSE:JNJ) about a transaction.
- Asked by SonntagsBlick whether Novartis could emerge as a white knight, he said: "We have always said that we will concentrate on complementary acquisitions in the range of $2B-$5B."
- Actelion is worth nearly $20B at Friday's closing price.
Fri, Dec. 2, 4:17 PM
- Bloomberg reports that, according to sources close to the matter, Johnson & Johnson's (NYSE:JNJ) bid for Actelion (OTCPK:ALIOY) is now north of $250, $4 above its initial offer of $246, which Actelion rejected.
- According to Mirabaud analyst Nick Turner, the revised bid, a modest 1.6% above the initial price, may get the job done.
- Previously: Actelion up 16% on higher bid from J&J (Nov. 29)
Thu, Dec. 1, 9:17 PM
- Johnson & Johnson (NYSE:JNJ) is ordered by a federal jury in Dallas to pay more than $1B to six plaintiffs who said they were injured by Pinnacle hip implants.
- The jurors said the hip implants were defectively designed and that JNJ and its DuPuy Orthopaedics unit failed to warn patients about the risks.
- JNJ, which still faces nearly 9K lawsuits over the implants, stopped selling the product in 2013 after the FDA toughened regulations on artificial hips; it plans to appeal the verdict.
Tue, Nov. 29, 3:28 PM
- Barclays' Geoff Meacham has downgraded BioMarin Pharmaceutical (BMRN -1.4%), Johnson & Johnson (JNJ -0.5%), Seattle Genetics (SGEN -0.2%), United Therapeutics (UTHR -4.1%) and Vertex Pharmaceuticals (VRTX -0.9%) to Equal Weight from Overweight.
- He trimmed BMRN's price target to $105 (21% upside) from $125 citing "moderating growth and an overall lack of catalysts in 2017."
- J&J's price target was sliced to $125 (11% upside) from $130 due to a "less compelling risk/reward profile."
- SGEN's fair value target was lowered to $53 (21% downside risk) from $70 due to valuation.
- UTHR's price target was revised to $100 (21% downside risk) from $115 citing the likely impact of Uptravi on Orenitram uptake.
- He lowered Vertex's price target to $90 (5% upside) from $100 citing the lack of upside for Kalydeco and Orkambi.
Tue, Nov. 29, 11:02 AM
Tue, Nov. 29, 6:49 AM
- Actelion (OTCPK:ALIOY) shares are down almost 6% in Zurich on reports that it is resisting Johnson & Johnson's (NYSE:JNJ) $17B offer for an outright sale. The aim of the complicated deal structure previously reported is to enable the company to remain independent while allowing J&J's U.S. group to retain a major equity stake.
- Lurking in the background is Sanofi (NYSE:SNY) which could jump into the mix considering its widely-known interest in acquisitions since it plans to divest its generics business. Sanofi shares are up over 1% in Paris.
Tue, Nov. 29, 2:50 AM
- Actelion (OTCPK:ALIOY) is considering a complicated deal to combine with part of Johnson & Johnson (NYSE:JNJ), a move that will leave the Swiss company independent from the U.S. drugs giant, FT reports.
- The structured transaction would create a new, larger biotech firm uniting Actelion with relevant parts of J&J's pharma business, with the latter becoming a major shareholder in the new business.
Mon, Nov. 28, 7:11 AM
- Johnson & Johnson's (NYSE:JNJ) Janssen Research & Development, LLC initiates an open-label Phase 2b study assessing the combination of simeprevir, odalasvir and JNJ-4178 (AL-335) in treatment-naive and treatment-experienced patients with chronic hepatitis C virus infection genotypes 1,2,4,5 and 6 without cirrhosis.
- Subjects will receive the triple combination for either six or eight weeks. The primary endpoint is the percentage of patients who achieve clinical cure (SVR12) at the end of treatment. According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is August 2017. The estimated study completion date is October 2017.
- An ongoing Phase 2b study is evaluating the triple combo regimen in HCV patients with or without compensated cirrhosis.
- Simeprevir (Olysio) is an NS3/4 protease inhibitor. Odalasvir is an NS5A inhibitor. JNJ-4178 (AL-335) is a novel uridine nucleotide analog polymerase inhibitor.
- Related tickers: (NASDAQ:GILD)(NYSE:ABBV)
Fri, Nov. 25, 12:11 PM
- Johnson & Johnson (JNJ +0.8%) confirms it's engaged in preliminary discussions with Actelion Pharmaceuticals (OTCPK:ALIOY) regarding a potential transaction.
- The company says it won't make any additional comments about the talks.
- Previously: Bloomberg: J&J makes takeover approach for Actelion (Nov. 25)Source: Press Release
Fri, Nov. 25, 1:52 AM
- Johnson & Johnson (NYSE:JNJ) has approached Actelion (OTCPK:ALIOY) about a potential takeover in a bid to boost its pharma business, Bloomberg reports.
- Europe's largest biotech firm has two pulmonary arterial hyper tension drugs which J&J would love to get its hands on, but deliberations are still at an early stage.
- Shares in Actelion are up around 13% so far this year, valuing the company at around $17B.
Mon, Nov. 21, 8:00 PM
- The FDA approves the use of Janssen Biotech's (NYSE:JNJ) DARZALEX (daratumumab), in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma (MM) who have received at least one prior line of therapy.
- The previous label was restricted to MM patients who had received at least three prior lines of therapy.
Fri, Nov. 18, 12:54 PM
- ViiV Healthcare, the HIV-focused company majority owned by GlaxoSmithKline (GSK -0.7%) and Pfizer (PFE -0.4%), initiates two Phase 3 studies assessing an injectable regimen of cabotegravir and rilpivirine for the treatment of HIV-1 infection. The studies, FLAIR and ATLAS, will evaluate the safety and efficacy of the two-drug combo, administered once per month, in both treatment-naive and treatment-experienced patients.
- According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is July/August 2018 for both studies. The estimated completion date for both is April/May 2022.
- Cabotegravir, developed by ViiV, in an integrase strand transfer inhibitor. It is also being evaluated in a tablet formulation.
- Rilpivirine [marketed as EDURANT by Janssen (JNJ -1.2%)] is a non-nucleoside reverse transcriptase inhibitor.
Thu, Nov. 17, 8:53 AM
- Johnson & Johnson's (NYSE:JNJ) Janssen Biotech submits its Biologics License Application (BLA) to the FDA seeking approval of guselkumab for the treatment of adults with moderate-to-severe plaque psoriasis.
- Guselkumab is a human monoclonal antibody that binds to interleukin 23 (IL-23), a pro-inflammatory cytokine. J&J expects it to be a blockbuster and one of its major growth drivers.
Tue, Nov. 15, 9:55 AM
- Results from a Phase 2 clinical trial assessing Janssen's (NYSE:JNJ) anti-interleukin 23 (IL-23) monoclonal antibody guselkumab in patients with psoriatic arthritis (PA) showed a significant treatment benefit compared to placebo. The data were presented at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting in Washington, D.C.
- The study met its primary endpoint of a statistically valid proportion of patients treated with guselkumab achieving ACR20 (20% improvement in PA symptoms) at week 24 versus placebo (58% vs. 18.4%; p<0.001). All secondary endpoints were also met.
- At week 16, the proportion of subjects achieving ACR20 also favored guselkumab (60% vs. 16.3%; p<0.001), as did those achieving ACR50 (34% vs. 10.2%; p=0.002) and PASI 75 (78.6% vs. 12.5%; p<0.001).
- Patients receiving guselkumab experienced greater improvements in enthesitis (inflammation at the sites where tendons & ligaments attach to bone) and dactylitis (inflammation of the fingers or toes).
- The incidence of adverse events (AEs) was 36.0% for guselkumab and 32.7% for placebo. The most common AEs were infections.
- The company announced positive results in a Phase 3 trial in plaque psoriasis last month.
- Previously: Janssen's psoriasis candidate guselkumab tops Humira in late-stage study (Oct. 3)